{"id":26266,"date":"2023-11-29T11:15:11","date_gmt":"2023-11-29T10:15:11","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=26266"},"modified":"2024-03-17T11:41:02","modified_gmt":"2024-03-17T10:41:02","slug":"impilo-to-invest-in-stille","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/impilo-to-invest-in-stille\/","title":{"rendered":"Impilo to invest in Stille"},"content":{"rendered":"<p class=\"preamble\">Impilo has undertaken to subscribe for shares in a directed share issue carried out by Stille AB (publ). Impilo\u2019s subscription undertaking, which corresponds to an investment amount of approximately SEK 220 million, is conditional upon e.g. an extraordinary general meeting of Stille approving the directed share issue, and Impilo\u2019s investment being approved by the Inspectorate of Strategic Products (Sw. <em>Inspektionen f\u00f6r strategiska produkter<\/em>) in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. <em>lagen (2023:560) om granskning av utl\u00e4ndska direktinvesteringar<\/em>).<\/p>\n<p>Stille AB develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s share is listed on Nasdaq First North Growth Market.<\/p>\n<p>Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in medical technology, pharmaceuticals, healthcare services, and other health-related areas.<\/p>\n<p>Impilo is advised by Mannheimer Swartling in connection with the investment in Stille.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Impilo has undertaken to subscribe for shares in a directed share issue carried out by Stille AB (publ). Impilo\u2019s subscription undertaking, which corresponds to an\u2026<\/p>\n","protected":false},"author":18,"featured_media":26264,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-26266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-eu-and-competition","business-group-private-equity","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":26266,"sv":26262},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26266"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=26266"}],"version-history":[{"count":1,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26266\/revisions"}],"predecessor-version":[{"id":26267,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26266\/revisions\/26267"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/26264"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=26266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=26266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=26266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}